Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
February 17, 2022 08:00 ET
|
Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS
July 16, 2020 08:00 ET
|
Daxor Corporation
Enrollment Commences Using the BVA-100® Diagnostic Blood Test NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical...
New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018
November 08, 2018 13:46 ET
|
Daxor Corporation
Daxor to Exhibit at American Heart Association 2018 NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation...